Cargando…
Multi-target tyrosine kinase inhibitor nanoparticle delivery systems for cancer therapy
Multi-target Tyrosine Kinase Inhibitors (MTKIs) have drawn substantial attention in tumor therapy. MTKIs could inhibit tumor cell proliferation and induce apoptosis by blocking the activity of tyrosine kinase. However, the toxicity and drug resistance of MTKIs severely restrict their further clinica...
Autores principales: | Xu, Wenjing, Ye, Chunping, Qing, Xin, Liu, Shengli, Lv, Xinyi, Wang, Wenjun, Dong, Xiaochen, Zhang, Yewei |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9307458/ https://www.ncbi.nlm.nih.gov/pubmed/35880099 http://dx.doi.org/10.1016/j.mtbio.2022.100358 |
Ejemplares similares
-
Molecular Characteristics, Clinical Significance, and Cancer Immune Interactions of Angiogenesis-Associated Genes in Gastric Cancer
por: Qing, Xin, et al.
Publicado: (2022) -
Solid Lipid Nanoparticles for Efficient Oral Delivery of Tyrosine Kinase Inhibitors: A Nano Targeted Cancer Drug Delivery
por: Satapathy, Sukanta, et al.
Publicado: (2022) -
Anlotinib: a novel multi-targeting tyrosine kinase inhibitor in clinical development
por: Shen, Guoshuang, et al.
Publicado: (2018) -
Drug delivery, biodistribution and anti-EGFR activity: theragnostic nanoparticles for simultaneous in vivo delivery of tyrosine kinase inhibitors and kinase activity biosensors
por: Bofinger, Robin, et al.
Publicado: (2021) -
Prodrug AST-003 Improves the Therapeutic Index of the Multi-Targeted Tyrosine Kinase Inhibitor Sunitinib
por: Huang, Qiang, et al.
Publicado: (2015)